[ad_1]
WASHINGTON – Pfizer said on Thursday it had started clinical trials of its Covid vaccine in children under eleven, an early sign of the next step in the global vaccination campaign.
“In collaboration with our partner BioNTech, we assayed the first healthy children in a continuous global phase 1/2/3 study to further assess the safety, tolerability and immunogenicity of the Pfizer-BioNTech COVID-19 vaccine” the company said in a statement to AFP.
“We are proud to launch this indispensable study for children and families who are eagerly awaiting a possible vaccine option.”
Receive The Times of Israel daily edition via email and never miss our best articles Sign up for free
According to details posted on clinictrials.gov, the company is testing three different dosage levels for use in this age group.
The company is already testing vaccines on children ages 12 to 15, and its US emergency clearance covers people ages 16 and older.
Pfizer is joining Moderna and AstraZeneca to test their vaccines in young children, while Johnson & Johnson plans to follow.
While children are generally spared the worst of the disease and are less likely than adults to transmit the virus, rare severe cases of Covid and death occur, along with a post-infectious inflammatory condition called MIS-C.
Those under the age of 18 make up about one-fifth of America’s population of 330 million, and most experts believe that advances in childhood immunization will be necessary in order to achieve population-level immunity.
I am proud to work at The Times of Israel
I’ll tell you the truth: life here in Israel is not always easy. But it is full of beauty and meaning.
I am proud to work at The Times of Israel alongside colleagues who dedicate their hearts to their work day in and day out to capture the complexity of this extraordinary place.
I believe our reporting sets an important tone of honesty and decency which is essential to understanding what is really going on in Israel. It takes a lot of time, commitment and hard work on the part of our team to achieve this.
Your support, by joining The Times of Israel community, allows us to continue our work. Would you like to join our community today?
thank you,
Sarah Tuttle Singer, Editor-in-Chief, New Media
Join The Times of Israel Community Join Our Community Already a member? Log in to stop seeing this
Are you serious. We appreciate this!
We are really glad you read X Times of Israel Articles in the past month.
That’s why we come to work every day – to provide knowledgeable readers like you with must-see coverage of Israel and the Jewish world.
So now we have a request. Unlike other media, we have not set up a payment wall. But since the journalism we do is expensive, we invite readers for whom The Times of Israel has become important to support our work by joining The Times of Israel community.
For as little as $ 6 per month, you can help support our quality journalism while benefiting from The Times of Israel WITHOUT ADVERTISING, as well as access to exclusive content available only to members of the Times of Israel community.
Join our community Join our community Already a member? Log in to stop seeing this
[ad_2]
Source link
